摘要
lisocabtagene maraleucel(Liso-cel)是靶向CD19的嵌合抗原受体(CAR)-T细胞,2021年2月5日,美国食品和药物管理局通过加速评审程序,批准Liso-cel用于治疗复发/难治大B细胞淋巴瘤的成人患者。Lisocel是由1:1固定比例的CD8^(+)和CD4^(+)T细胞组成,相较于单一的CAR-T细胞亚群,其在治疗B细胞恶性肿瘤时具有更强的增殖能力及抗肿瘤活性。最新研究显示,接受Liso-cel治疗的患者客观缓解率为72.7%,常见不良反应包括中性粒细胞减少、贫血和疲劳等。
Lisocabtagene maraleucel(Liso-cel), CD19-directed chimeric antigen receptor(CAR)-T cell,was approved by the U.S. Food and Drug Administration in the treatment of adult patients with relapsed/refractory large B-cell lymphoma through the accelerated review proces on February 5, 2021. Liso-cel is composed of a 1:1 fixed ratio of CD8^(+) and CD4^(+) T cells. Compared with a single CAR-T cell subpopulation, it has stronger proliferative and antitumor activity in B-cell malignancies. The latest studies have shown that the overall response rate was 72.7% in patients who received Liso-cel, and common adverse reactions include neutropenia, anemia, fatigue and so on.
作者
郭仁芬
邢孔浪
柴芳
邓黎黎
GUO Ren-fen;XING Kong-lang;CHAI Fang;DENG Li-li(Department of Pharmacy,People's Hospital of Sanya,Sanya HAINAN 572000,China;Department of Oncology,People's Hospital of Sanya,Sanya HAINAN 572000,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2022年第4期206-210,共5页
Chinese Journal of New Drugs and Clinical Remedies
